Anticorps OCIL (166C1309): sc-52905

Osteoclast inhibitory lectin (OCIL) is a type II membrane-bound C-type lectin that binds natural killer cell-associated receptors NKR-P1D and sulfated glycosaminoglycans. Expressed in osteoblasts, chondrocytes and also a variety of extraskeletal tissues, OCIL inhibits multinucleate osteoclast differentiation and function through the binding of its cognate receptor NKR-P1D. OCIL also prohibits primary osteoblast and KUSA O cell associated natural killer cell-mediated cytotoxicity and mineralization. OCIL mRNA expression acts directly on macrophage cells by devastating stromal and lymphocytic cells. Osteoblast OCIL mRNA expression magnifies through exposure to parathyroid hormone, calcitriol, retinoic acid, IL-1 and IL-11. OCIL may affect mesenchymal lineage in ways that may be necessary for bone metabolism and the function of other connective tissues.